Literature DB >> 24392683

Additional local therapy with primary re-excision or radiation therapy improves survival and local control after incomplete or close surgical excision of mast cell tumors in dogs.

Kristin L Kry1, Sarah E Boston.   

Abstract

OBJECTIVE: To compare survival and local recurrence outcomes in dogs with mast cell tumors with incomplete or close margins treated with primary re-excision or radiation therapy of the primary site versus no additional local therapy. STUDY
DESIGN: Retrospective case series. ANIMALS: Dogs (n = 64).
METHODS: Outcomes of canine mast cell tumor cases that had incomplete or close surgical resection and presented to the Ontario Veterinary College Health Sciences Centre (2001-2010) were evaluated after additional local therapy (primary re-excision or radiation therapy) or no additional local therapy (comparison). Follow-up was performed through evaluation of medical records and telephone contact with referring veterinarians and owners.
RESULTS: Tumors (n = 70) in 64 dogs were studied. Median survival times for the primary re-excision (2930 days) and radiation therapy (2194 days) groups were significantly longer than for the comparison (710 days) group. Local recurrence occurred in 13% of the re-excision group, 8% of the radiation therapy group, and 38% of the comparison group. Although local recurrence rate was not statistically significant for the re-excision group, time to local recurrence was statistically longer for both the re-excision and radiation groups. Adjunctive chemotherapy was not associated with improved survival or local control. CONCLUSION/CLINICAL RELEVANCE: There is significant improvement in survival and duration of local control when additional local therapy is performed after incomplete or close resection of mast cell tumors. These follow-up therapies should be recommended to owners when mast cell tumors are incompletely or closely resected. © Copyright 2014 by The American College of Veterinary Surgeons.

Entities:  

Keywords:  dog; incomplete resection; mast cell tumor; radiation therapy; surgical resection

Mesh:

Year:  2014        PMID: 24392683     DOI: 10.1111/j.1532-950X.2014.12099.x

Source DB:  PubMed          Journal:  Vet Surg        ISSN: 0161-3499            Impact factor:   1.495


  9 in total

1.  Predictive ability of fine-needle aspirate cytology for incompletely resected mast cell tumor surgical sites.

Authors:  Christopher E Lee; Stephanie S Lindley; Annette N Smith; Philippe Gaillard; Ralph A Henderson; Brad M Matz
Journal:  Can Vet J       Date:  2021-02       Impact factor: 1.008

2.  Combination vinblastine and palladia for high-grade and metastatic mast cell tumors in dogs.

Authors:  Johanna E Todd; Sandra M Nguyen; Joanna White; Veronika Langova; Penelope M Thomas; Sophia Tzannes
Journal:  Can Vet J       Date:  2021-12       Impact factor: 1.008

3.  Histological classification and expression of markers of canine mast cell tumors.

Authors:  V S Cruz; J C A Borges; L L Nepomuceno; P A M Gonçalves; Y C L Prado; C Bianchi; M C S Fioravanti; E G Araújo
Journal:  Vet World       Date:  2020-08-18

4.  Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs.

Authors:  Jaime A Olsen; Maurine Thomson; Kathleen O'Connell; Ken Wyatt
Journal:  Vet Med Sci       Date:  2018-05-24

Review 5.  Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms.

Authors:  Michael Willmann; Emir Hadzijusufovic; Olivier Hermine; Mauro Dacasto; Laura Marconato; Karin Bauer; Barbara Peter; Susanne Gamperl; Gregor Eisenwort; Erika Jensen-Jarolim; Mathias Müller; Michel Arock; David M Vail; Peter Valent
Journal:  Vet Comp Oncol       Date:  2018-09-24       Impact factor: 2.613

Review 6.  Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors.

Authors:  Andrigo Barboza de Nardi; Rodrigo Dos Santos Horta; Carlos Eduardo Fonseca-Alves; Felipe Noleto de Paiva; Laís Calazans Menescal Linhares; Bruna Fernanda Firmo; Felipe Augusto Ruiz Sueiro; Krishna Duro de Oliveira; Silvia Vanessa Lourenço; Ricardo De Francisco Strefezzi; Carlos Henrique Maciel Brunner; Marcelo Monte Mor Rangel; Paulo Cesar Jark; Jorge Luiz Costa Castro; Rodrigo Ubukata; Karen Batschinski; Renata Afonso Sobral; Natália Oyafuso da Cruz; Adriana Tomoko Nishiya; Simone Crestoni Fernandes; Simone Carvalho Dos Santos Cunha; Daniel Guimarães Gerardi; Guilherme Sellera Godoy Challoub; Luiz Roberto Biondi; Renee Laufer-Amorim; Paulo Ricardo de Oliveira Paes; Gleidice Eunice Lavalle; Rafael Ricardo Huppes; Fabrizio Grandi; Carmen Helena de Carvalho Vasconcellos; Denner Santos Dos Anjos; Ângela Cristina Malheiros Luzo; Julia Maria Matera; Miluse Vozdova; Maria Lucia Zaidan Dagli
Journal:  Cells       Date:  2022-02-10       Impact factor: 6.600

7.  Outcomes of adjunctive radiation therapy for the treatment of mast cell tumors in dogs and assessment of toxicity: A multicenter observational study of 300 dogs.

Authors:  Sarah L Mason; Charles Pittaway; Begona Pons Gil; Onne-Marju Russak; Katie Westlake; Davide Berlato; Jérôme Benoit; Joanna Morris; Jane Margaret Dobson
Journal:  J Vet Intern Med       Date:  2021-10-21       Impact factor: 3.333

8.  Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors: A Pilot Study.

Authors:  Shawna Klahn; Nikolaos Dervisis; Kevin Lahmers; Marian Benitez
Journal:  Vet Sci       Date:  2022-06-07

9.  Recurrence-free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate.

Authors:  Pamela D Jones; Justine E Campbell; Graham Brown; Chad M Johannes; Paul Reddell
Journal:  J Vet Intern Med       Date:  2020-12-22       Impact factor: 3.175

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.